Command Palette

Search for a command to run...

Clinical Trials · NCT02198209

Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

WithdrawnPhase 4Liraglutide (Prohibited)
Phase
Phase 4
Recruitment status
Withdrawn
Sponsor
Cedars-Sinai Medical Center
Enrollment
0
Start date
Dec 2019
Locations
1 site, United States
Primary endpoint
Liver glucokinase activity (acute effect)
View Liraglutide compound reference